On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...